Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

GlucoTrack, Inc. - Common Stock (NQ:GCTK)

0.8004 -0.0596 (-6.93%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GlucoTrack, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Glucotrack Announces IDE Submission for U.S. Clinical Study of its Novel Implantable Continuous Blood Glucose Monitoring Technology
Submission supports advancement of a long‑term, fully implantable, blood‑based continuous glucose monitoring platform 
From Glucotrack, Inc.
Via GlobeNewswire
Wednesday's session: most active stocks ↗
Via Chartmill
Unusual volume stocks in Wednesday's session ↗
Via Chartmill
Keep an eye on the top gainers and losers in Wednesday's session. ↗
Via Chartmill
Wednesday's session: gap up and gap down stocks ↗
Via Chartmill
These stocks are moving in today's pre-market session ↗
Via Chartmill
News headline image
Glucotrack Announces Publication of Peer-Reviewed Study In The Journal of Diabetes Research Demonstrating Long-Term Accuracy and Stability of Continuous Blood Glucose Monitoring Technology
In-Vivo Ovine Study Demonstrates Sustained Performance Of Company’s Continuous Blood Glucose Monitoring (CBGM) Technology Over 240 Days, Reinforces Path to Key IDE Submission 
From Glucotrack, Inc.
Via GlobeNewswire
Get insights into the top gainers and losers of Thursday's pre-market session. ↗
Via Chartmill
Check out the stocks that are attracting the most attention and driving market activity. ↗
Via Chartmill
Get insights into the top gainers and losers of Wednesday's pre-market session. ↗
Via Chartmill
News headline image
Glucotrack Announces Publication of Peer-Reviewed Study Supporting Long-Life Sensor Design for Implantable Continuous Blood Glucose Monitoring Technology
Year-long in-vitro characterization of glucose oxidase stability supports the feasibility of long-life implantable continuous glucose monitors, independent third party review of the longevity and... 
From Glucotrack, Inc.
Via GlobeNewswire
News headline image
Tuesday's session: gap up and gap down stocks ↗
Let's have a look at the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Wondering what's happening in Tuesday's pre-market session? Find an overview in this article. 
Via Chartmill
News headline image
These stocks are moving in today's after hours session ↗
After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
What's going on in today's session ↗
Looking for insights into the US markets in the middle of the day on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
Monday's after hours session: top gainers and losers ↗
Via Chartmill
Which stocks are experiencing notable movement on Monday? ↗
Via Chartmill
Here are the top movers in Monday's session. ↗
Via Chartmill
Which stocks are gapping on Friday? ↗
Via Chartmill
What's going on in today's pre-market session ↗
Via Chartmill
News headline image
Glucotrack to File Significant IDE with FDA for US Clinical Trial in Early Q2 Based on Critical 2025 Milestones
Experience From Brazilian and Australian Clinical Trials Positions the Company to Submit Investigational Device Exemption (IDE) to FDA for Novel CBGM Technology in Q2 2026 
From Glucotrack, Inc.
Via GlobeNewswire
News headline image
Glucotrack to Present at LSI USA ’26 Medtech Innovation Summit
From Glucotrack, Inc.
Via GlobeNewswire
News headline image
Why Did Glucotrack Stock Surge 12% Pre-Market Today? ↗
The company has received patents for its continuous blood glucose monitoring system. 
Via Stocktwits
Topics Intellectual Property
News headline image
Glucotrack Announces USPTO Approval for Issuance of Patents for Proprietary CBGM Platform
From Glucotrack, Inc.
Via GlobeNewswire
News headline image
Glucotrack, Inc. Encourages Shareholders to Vote
From Glucotrack, Inc.
Via GlobeNewswire
News headline image
Glucotrack Appoints Neuromodulation and Painful Diabetic Neuropathy Expert, Usman Latif, MD, MBA, to Clinical Advisory Team
Renowned pain management and medical technology leader to accelerate Glucotrack’s strategy for integrated glucose monitoring applications, building on Company’s 2024 expansion into epidural monitoring 
From Glucotrack, Inc.
Via GlobeNewswire
News headline image
Wondering what's happening in today's after-hours session? ↗
As the regular session of the US market on Tuesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Glucotrack, Inc. Reminds Shareholders to Vote
From Glucotrack, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.